Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia …
T Lange, T Bumm, S Otto, HK Al-Ali, I Kovacs… - …, 2004 - haematologica.org
BACKGROUND AND OBJECTIVES: Imatinib is the new standard drug treatment for patients
with chronic myelogenous leukemia (CML). Quantitative reverse transcription-polymerase …
with chronic myelogenous leukemia (CML). Quantitative reverse transcription-polymerase …
Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL
Real-time quantitative polymerase chain reaction (PCR) for BCR-ABL mRNA in the
peripheral blood (RQ-PCR) provides an accurate and reliable measure of response to …
peripheral blood (RQ-PCR) provides an accurate and reliable measure of response to …
Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission
M Serpa, SS Sanabani, PE Dorliac-Llacer, M Conchon… - BMC Hematology, 2010 - Springer
Background The monitoring of BCR-ABL transcript levels by real-time quantitative
polymerase chain reaction (RT-qPCR) has become important to assess minimal residual …
polymerase chain reaction (RT-qPCR) has become important to assess minimal residual …
Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate
M Hardling, Y Wei, L Palmqvist, B Swolin… - Medical oncology, 2004 - Springer
Survival among chronic myelogenous leukemia (CML) patients can be linked to the
reduction in leukemic cell burden. Treatment with imatinib mesylate results in a high …
reduction in leukemic cell burden. Treatment with imatinib mesylate results in a high …
[HTML][HTML] Equivalence of BCR-ABL Transcript Levels< 1% According to the International Scale with Complete Cytogenetic Response in Chronic Phase CML Patients.
M Lauseker, B Hanfstein, C Haferlach, S Schnittger… - Blood, 2012 - Elsevier
Abstract Abstract 2495 Introduction: Response to therapy in patients with chronic myeloid
leukemia (CML) is monitored by both cytogenetic assessment of bone marrow metaphases …
leukemia (CML) is monitored by both cytogenetic assessment of bone marrow metaphases …
[HTML][HTML] BCR-ABL RNA Levels at the Time of a Complete Cytogenetic Response (CCR) Predict the Duration of CCR in Imatinib-Treated Chronic Myeloid Leukemia …
RD Press, Z Love, AA Tronnes, G Kurilik, MJ Mauro… - Blood, 2004 - Elsevier
Background: Imatinib induces a complete cytogenetic response (CCR) in the majority of
patients with chronic phase CML. CCR is durable in the majority of patients, but relapse …
patients with chronic phase CML. CCR is durable in the majority of patients, but relapse …
Significant Discrepancy In Peripheral Blood Compared to Bone Marrow BCR-ABL Transcript Levels In Chronic Phase Chronic Myeloid Leukemia (CML)
JN Berman, W Greer, R Juskevicius, CV Fernandez… - 2010 - ashpublications.org
Abstract 4471 Chronic myeloid leukemia (CML) is associated with the reciprocal t (9;
22)(q34; q11) translocation, which generates the BCR-ABL fusion oncogene and is the most …
22)(q34; q11) translocation, which generates the BCR-ABL fusion oncogene and is the most …
Optimizing early prediction of outcome in CML using the exact decline of BCR-ABL transcript levels within 3 months of imatinib treatment as a prognostic marker
B Hanfstein, V Shlyakhto, M Lauseker, R Hehlmann… - 2013 - ashpublications.org
Introduction Early assessment of BCR-ABL transcript levels at 3 months allows the
prediction of survival and may serve as a trigger for treatment intensification in CML patients …
prediction of survival and may serve as a trigger for treatment intensification in CML patients …
Monitoring Minimal Residual Disease by Quantitative PCR in Chronic Myeloid Leukemia Patients in Complete Cytogenetic Remission
C Pavlovsky, I Giere, V Lombardi, P Negri, B Moiraghi… - 2008 - ashpublications.org
The landscape of chronic myeloid leukemia (CML) has radically changed since the
introduction of tyrosine kinase inhibitor (TKI), imatinib (IM), now considered as standard …
introduction of tyrosine kinase inhibitor (TKI), imatinib (IM), now considered as standard …
Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α
K Merx, MC Müller, S Kreil, T Lahaye, P Paschka… - Leukemia, 2002 - nature.com
The degree of tumor load reduction as measured by cytogenetic response is an important
prognostic factor for chronic myelogenous leukemia (CML) patients on therapy. We sought …
prognostic factor for chronic myelogenous leukemia (CML) patients on therapy. We sought …